These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

120 related items for PubMed ID: 16216757

  • 1. Does treatment with ACE inhibitors or angiotensin II receptor antagonists prevent atrial fibrillation after dual chamber pacemaker implantation?
    Williams SG, Connelly DT, Jackson M, Bennett A, Albouaini K, Todd DM.
    Europace; 2005 Nov; 7(6):554-9. PubMed ID: 16216757
    [Abstract] [Full Text] [Related]

  • 2. Therapy with angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and statins: no effect on ablation outcome after ablation of atrial fibrillation.
    Richter B, Derntl M, Marx M, Lercher P, Gössinger HD.
    Am Heart J; 2007 Jan; 153(1):113-9. PubMed ID: 17174648
    [Abstract] [Full Text] [Related]

  • 3. Inefficiency of renin-angiotensin inhibitors in preventing atrial fibrillation in patients with a normal heart.
    Fazio G, Pizzuto C, Sutera L, Guttilla D, Di Gesaro G, Cascio C, Novo G, Assennato P, Novo S.
    Minerva Cardioangiol; 2007 Jun; 55(3):311-5. PubMed ID: 17534249
    [Abstract] [Full Text] [Related]

  • 4. The effects of statins and renin-angiotensin system blockers on atrial fibrillation recurrence following antral pulmonary vein isolation.
    Al Chekakie MO, Akar JG, Wang F, Al Muradi H, Wu J, Santucci P, Varma N, Wilber DJ.
    J Cardiovasc Electrophysiol; 2007 Sep; 18(9):942-6. PubMed ID: 17593228
    [Abstract] [Full Text] [Related]

  • 5. Beneficial effects of statin therapy for prevention of atrial fibrillation following DDDR pacemaker implantation.
    Gillis AM, Morck M, Exner DV, Soo A, Rose MS, Sheldon RS, Duff HJ, Kavanagh KM, Mitchell LB, Wyse DG.
    Eur Heart J; 2008 Aug; 29(15):1873-80. PubMed ID: 18477727
    [Abstract] [Full Text] [Related]

  • 6. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
    Okin PM, Wachtell K, Kjeldsen SE, Julius S, Lindholm LH, Dahlöf B, Hille DA, Nieminen MS, Edelman JM, Devereux RB.
    Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
    [Abstract] [Full Text] [Related]

  • 7. Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.
    Makkar KM, Sanoski CA, Spinler SA.
    Pharmacotherapy; 2009 Jan; 29(1):31-48. PubMed ID: 19113795
    [Abstract] [Full Text] [Related]

  • 8. Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.
    Lévy S.
    Nat Clin Pract Cardiovasc Med; 2006 Apr; 3(4):220-5. PubMed ID: 16568131
    [Abstract] [Full Text] [Related]

  • 9. Increased base rate of atrial pacing for prevention of atrial fibrillation after implantation of a dual-chamber pacemaker: insights from the Atrial Overdrive Pacing Study.
    Kantharia BK, Freedman RA, Hoekenga D, Tomassoni G, Worley S, Sorrentino R, Steinhaus D, Wolkowicz JM, Syed ZA, AOP Study Investigators.
    Europace; 2007 Nov; 9(11):1024-30. PubMed ID: 17913697
    [Abstract] [Full Text] [Related]

  • 10. Atorvastatin prevents atrial fibrillation in patients with bradyarrhythmias and implantation of an atrial-based or dual-chamber pacemaker: a prospective randomized trial.
    Tsai CT, Lai LP, Hwang JJ, Wang YC, Chiang FT, Lin JL.
    Am Heart J; 2008 Jul; 156(1):65-70. PubMed ID: 18585498
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.
    Salehian O, Healey J, Stambler B, Alnemer K, Almerri K, Grover J, Bata I, Mann J, Matthew J, Pogue J, Yusuf S, Dagenais G, Lonn E, HOPE Investigators.
    Am Heart J; 2007 Sep; 154(3):448-53. PubMed ID: 17719288
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation.
    L'Allier PL, Ducharme A, Keller PF, Yu H, Guertin MC, Tardif JC.
    J Am Coll Cardiol; 2004 Jul 07; 44(1):159-64. PubMed ID: 15234426
    [Abstract] [Full Text] [Related]

  • 17. Duration of P-wave is associated with atrial fibrillation hospitalizations in patients with atrial fibrillation and paced for bradycardia.
    Padeletti L, Santini M, Boriani G, Botto G, Ricci R, Spampinato A, Vergara G, Rahue WG, Capucci A, Gulizia M, Pieragnoli P, Grammatico A, Platonov P, Barold SS.
    Pacing Clin Electrophysiol; 2007 Aug 07; 30(8):961-9. PubMed ID: 17669078
    [Abstract] [Full Text] [Related]

  • 18. Atrial fibrillation after radiofrequency ablation of atrial flutter: preventive effect of angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, and diuretics.
    Anné W, Willems R, Van der Merwe N, Van de Werf F, Ector H, Heidbüchel H.
    Heart; 2004 Sep 07; 90(9):1025-30. PubMed ID: 15310691
    [Abstract] [Full Text] [Related]

  • 19. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion.
    Loricchio ML, Cianfrocca C, Pasceri V, Bianconi L, Auriti A, Calo L, Lamberti F, Castro A, Pandozi C, Palamara A, Santini M.
    Am J Cardiol; 2007 May 15; 99(10):1421-4. PubMed ID: 17493472
    [Abstract] [Full Text] [Related]

  • 20. Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial.
    Schmieder RE, Kjeldsen SE, Julius S, McInnes GT, Zanchetti A, Hua TA, VALUE Trial Group.
    J Hypertens; 2008 Mar 15; 26(3):403-11. PubMed ID: 18300848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.